Home Alzheimer’s Disease Pembrolizumab Bests Docetaxel in 5-Year Survival in PD-L1+ Advanced NSCLC

Pembrolizumab Bests Docetaxel in 5-Year Survival in PD-L1+ Advanced NSCLC

After more than 5 years of follow-up for the phase 2/3 KEYNOTE-010 trial (NCT01905657), pembrolizumab (Keytruda) continues to outperform docetaxel as therapy for patients with previously treated, PD-L1–positive advanced non–small cell lung cancer (NSCLC) based on clinically meaningful differences in overall (OS) and progression-free survival (PFS).1

“We continue to see a clinically meaningful improvement in OS and PFS. Five-year rates more than doubled in the pembrolizumab-treated patients for overall survival, compared with those receiving docetaxel,” Roy S. Herbst, MD, PhD, ensign professor of medicine and professor of pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, and associate cancer center director for translational research, Yale Cancer Center, said during a virtual presentation of the follow-up results that were presented at the…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments